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DownPurpose: The ISTANA (IRESSA as Second-line Therapy in Advanced NSCLC—KoreA) study compared
gefitinib with docetaxel in patients with advanced or metastatic non–small cell lung carcinoma
(NSCLC) pretreated with platinum-based chemotherapy.
Experimental Design: We conducted a multicenter, randomized, open-label phase III trial of gefiti-
nib (250 mg/d) versus docetaxel (75 mg/m2 day 1 every 3 weeks) in patients with advanced or meta-
static NSCLC treated with one previous platinum-based chemotherapy. The primary endpoint was
progression-free survival.
Results: A total of 161 patients (male, 62%; never smoker, 41%; adenocarcinoma, 68%) were en-
rolled. Progression-free survival was longer for gefitinib compared with docetaxel (hazard ratio, 0.729;
90% confidence interval, 0.533-0.998; one-sided P = 0.0441). Gefitinib significantly improved objective
response rate (28.1% versus 7.6%; two-sided P = 0.0007). In the final analysis of overall survival, the
hazard ratio was 0.870 (95% confidence interval, 0.613-1.236; two-sided P = 0.4370). No significant
differences were seen in the quality of life or symptom improvement rates between the two treatment
groups. Gefitinib was well tolerated, was consistent with previous data and disease, and had fewer se-
rious adverse events and fewer Common Terminology Criteria for Adverse Events grade 3 or 4 adverse
events than docetaxel. The incidence of interstitial lung disease–type events was 3.7% (n = 3) with
gefitinib and 3.9% (n = 3) with docetaxel.
Conclusions: The primary endpoint of progression-free survival was longer with gefitinib than doc-
etaxel, and the secondary endpoints showed superior objective response rate, good tolerability, and
similar quality of life improvement rates for gefitinib than docetaxel. Therefore, gefitinib is an impor-
tant valid treatment option for second-line therapy for Korean NSCLC patients. Clin Cancer Res; 16(4);
1307–14. ©2010 AACR.Gefitinib (Iressa, AstraZeneca) is an oral epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitor.
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Researc
on Decembclincancerres.aacrjournals.org loaded from subsequent phase III study in patients with pretreated re-
fractory NSCLC, not suitable for further chemotherapy,
showed a numerical improvement in overall survival with
gefitinib over placebo, although this failed to reach statisti-
cal significance in the overall study population (3). How-
ever, preplanned subgroup analyses found a significant
survival advantage for gefitinib compared with placebo
among patients of Asian origin and patients who had never
smoked (3, 4).
Docetaxel was approved for the treatment of locally ad-
vanced or metastatic NSCLC after failure of previous plat-
inum-based chemotherapy following two phase III studies
that showed that docetaxel improved survival and quality
of life compared with best supportive care (5) and with
chemotherapy with vinorelbine and ifosfamide (6). How-
ever, docetaxel is associatedwith significant toxicity, includ-
ing hematological toxicity, neurotoxicity, and asthenia.
Based on those findings, we conducted a phase III trial
to compare the efficacy and safety of gefitinib with doce-
taxel as second-line therapy in Korean patients with locally1307
h. 
er 23, 2013. © 2010 American Association for Cancer
Translational Relevance
This IRESSA as Second-line Therapy in Advanced
NSCLC—KoreA study was the first randomized phase
III study showing the advantage of molecularly targeted
therapy over cytotoxic chemotherapy as second-line
therapy for non–small cell lung cancer. Furthermore,
the patients enrolled differed from those in Western
studies in that all of them were Koreans or East Asians
and 41% of them were never smokers. We have proven
that a single molecular targeted agent can surpass cyto-
toxic chemotherapy in terms of survival outcome, as
well as toxicity or quality of life.
Lee et al.
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Published OnlineFirst February 15, 2010; DOI: 10.1158/1078-0432.CCR-09-1903 advanced or metastatic NSCLC who had previously re-
ceived platinum-based chemotherapy.Patients and Methods
Patients. This study (IRESSA as Second-line Therapy in
Advanced NSCLC—KoreA, ISTANA; study number
D7913L00039) included patients with histologically or cy-Clin Cancer Res; 16(4) February 15, 2010
Researc
on Decembclincancerres.aacrjournals.org Downloaded from tologically confirmed NSCLC with stage IIIB or IV disease
who had received only one previous platinum-doublet che-
motherapy regimen and who were considered candidates
for further chemotherapy. The main inclusion criteria were
age of 18 y or older, a WHO performance status of 0 to 2,
progressive or recurrent disease following previous chemo-
therapy (adjuvant chemotherapy was allowed if full cyto-
toxic doses of platinum-based doublet therapy was given
in patients with early disease having progressed), measur-
able disease by Response Evaluation Criteria In Solid Tu-
mors (RECIST), and adequate bone marrow, renal, and
hepatic function. However, patients with previous docetax-
el or any other EGFR-targeted treatment, any evidence of
clinically active interstitial lung disease, newly diagnosed
central nervous system metastases, or any unresolved
chronic toxicity greater than National Cancer Institute
Common Terminology Criteria for Adverse Events grade 2
from previous anticancer therapy were ineligible. All pa-
tients provided written informed consent before starting
the study. The study was approved by Institutional Review
Boards at every institution andwas done in accordance with
the Declaration of Helsinki and the International Confer-
ence on Harmonization/Good Clinical Practice.
Study design. ISTANA was a randomized, open-label,
parallel-group, multicentre phase III study. Eligible pa-
tients were randomly assigned to receive gefitinib orh. 
er 23, 2013. © 2010 AmerFig. 1. Patient flow through the trial.Clinical Cancer Research
ican Association for Cancer
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Published OnlineFirst February 15, 2010; DOI: 10.1158/1078-0432.CCR-09-1903 docetaxel after stratification for histology (adenocarcino-
ma versus other), gender (male versus female), perfor-
mance status (0 or 1 versus 2), best response to
previous therapy (refractory versus received), smoking
history (ever versus never), and participating center. Re-
fractory to previous therapy was defined as progression
on or within 3 mo of completing the previous therapy.
Patients received either 250 mg/d gefitinib orally or 75
mg/m2 docetaxel as a 1-h i.v. infusion on day 1 every 3
wk. Patients received treatment with gefitinib or docetax-
el until disease progression, unacceptable toxicity, or pa-
tient's withdrawal of consent, and for docetaxel, only
the maximum administration of 6 cycles was reached.
For patients receiving 250 mg/d gefitinib, dose interrup-
tions were permitted to manage toxicity, whereas for
those receiving docetaxel, the dose could be reduced
to 60 mg/m2, with standard premedication administered
until discontinuation of the treatment. Disease progres-
sion was to be documented radiologically using RECIST
criteria. However, for patients who had convincing evi-www.aacrjournals.org
Researc
on Decembclincancerres.aacrjournals.org Downloaded from dence of “clinical progression,” such as worsening of
performance status that was clearly cancer related but
could not be documented radiologically, the decision
on discontinuation of study therapy was made on a
case-by-case basis following discussion with the study
sponsor.
Progression-free survival was assessed from the date of
randomization to the earliest date of disease progression
by RECIST or death due to any cause. Tumor response by
RECIST was assessed after 3 wk of each treatment and
then every 6 wk. Overall survival was assessed from the
date of randomization to date of death due to any cause.
Changes in quality of life were assessed with the Func-
tional Assessment of Cancer Therapy—Lung (FACT-L)
questionnaire every 3 wk. From FACT-L, the following
scores were calculated: the FACT-L total score, the Trial
Outcome Index (sumof the physical, functional well-being,
and Lung Cancer Subscale scores), and Lung Cancer Sub-
scale score. Clinically relevant improvement was pre-
defined as a 6-point improvement of FACT-L total scoreTable 1. Patient demographics and disease characteristics at baseline (intent-to-treat population)Gefitinib (n = 82)Clin Cancer Res; 16
h. 
er 23, 2013. © 2010 American AssocDocetaxel (n = 79)Median age (range), y 57 (21-74) 58 (20-73)
Sex, n (%)Male 55 (67.1) 45 (57.0)
Female 27 (32.9) 34 (43.0)WHO PS, n (%)
0 2 (2.4) 3 (3.8)
1 74 (90.2) 71 (89.9)
2 6 (7.3) 5 (6.3)Smoking history, n (%)
Never smoker 30 (36.6) 36 (45.6)
Exsmoker 51 (62.2) 43 (54.4)
Regular smoker 1 (1.2) 0 (0.0)Tumor histology, n (%)
Adenocarcinoma 54 (65.9) 55 (69.6)
Squamous cell 17 (20.7) 11 (13.9)
Undifferentiated 7 (8.5) 9 (11.4)
Bronchioloalveolar 1 (1.2) 0 (0.0)
Mixed squamous and adenocarcinoma 1 (1.2) 1 (1.3)
Other 2 (2.4) 3 (3.8)Best response to previous therapy, n (%)
CR 0 (0.0) 0 (0.0)
PR 28 (34.1) 30 (38.0)
SD 33 (40.2) 29 (36.7)
Progression 20 (24.4) 19 (24.1)
Unknown 0 (0.0) 1 (1.3)
Nonevaluable 1 (1.2) 0 (0.0)Disease stage
Locally advanced 11 (13.4) 14 (17.7)
Metastatic 71 (86.6) 65 (82.3)Abbreviations: PS, performance status; CR, complete response; PR, partial response; SD, stable disease.(4) February 15, 2010 1309
iation for Cancer
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Published OnlineFirst February 15, 2010; DOI: 10.1158/1078-0432.CCR-09-1903 and Trial Outcome Index and 2-point improvement of
Lung Cancer Subscale maintained for at least 3 wk. Ad-
verse events were monitored and graded by National Can-
cer Institute Common Terminology Criteria for Adverse
Events version 3.0.
Statistical analysis. One hundred fifty patients were
planned to be recruited to this trial. A total of 120 eventsClin Cancer Res; 16(4) February 15, 2010
Researc
on Decembclincancerres.aacrjournals.org Downloaded from in these patients were needed to detect superior progres-
sion-free survival for gefitinib over docetaxel using a
one-sided test at the 5% significance level [90% confi-
dence interval (90% CI)] with 80% power if the true haz-
ard ratio was 0.63.
An unadjusted Cox proportional hazards model was
used to analyze progression-free survival and overallClinical Cancer Research
h. 
er 23, 2013. © 2010 American Association for CancerFig. 3. Kaplan-Meier curves
for overall survival. Analysis
without covariates (intent-to-treat
population). Hazard ratio < 1
implies a lower risk for progression
on gefitinib.Fig. 2. Kaplan-Meier curves for
progression-free survival. Primary
analysis without covariates
(intent-to-treat population). Hazard
ratio < 1 implies a lower risk for
progression on gefitinib. HR,
hazard ratio; PFS, progression-
free survival.
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Published OnlineFirst February 15, 2010; DOI: 10.1158/1078-0432.CCR-09-1903 survival (two-sided test at the 5% significance level; 95%
CI) to compare the treatment groups. Supportive analy-
ses using a Cox proportional hazards model adjusting
for gender, histology, smoking history, stage, and perfor-
mance status were also done. Objective response rate,
quality of life improvement rates, and symptom im-
provement were compared between the two treatment
groups using the χ2 test (two-sided test at the 5% sig-
nificance level; 95% CI). All efficacy analyses were done
in the intent-to-treat population. This study has been
submitted for registration with ClinicalTrials.gov identifi-
er NCT00478049.
Results
Patient characteristics. From September 2005 to Sep-
tember 2006, 161 patients from six centers in Korea
were randomized to gefitinib (n = 82) or docetaxel (n
= 79; Fig. 1). The treatment groups were well balanced
for baseline characteristics (Table 1), with the exception
of slightly fewer females (33% versus 43%) and never
smokers (37% versus 46%) in the gefitinib treatment
group than in the docetaxel group.
Efficacy endpoints. By January 2, 2007, 120 disease pro-
gressions had occurred (61 in the gefitinib treatment
group and 59 in the docetaxel treatment group). Progres-
sion-free survival was found to be longer on gefitinib com-
pared with docetaxel; the progression-free survival hazard
ratio for gefitinib derived from the primary unadjusted
model was 0.729 (90% CI, 0.533-0.988; one-sided P =
0.0441; Fig. 2) and from the supportive adjusted model
was 0.634 (90% CI, 0.459-0.875; one-sided P = 0.0134).
Median progression-free survival was 3.3 months in the
gefitinib group and 3.4 months in the docetaxel group;
6-month progression-free survival rates were 32% and
13%, respectively. In terms of objective response rate
(complete response plus partial response), gefitinib was
statistically superior to docetaxel (28.1% versus 7.6%; P
= 0.0007). A preliminary analysis of overall survival was
conducted at the time of data cutoff of January 2, 2007,
whereas 55 deaths had occurred (27 in the gefitinib treat-
ment group and 28 in the docetaxel treatment group); the
hazard ratio was 0.606 (95% CI, 0.350-1.049), which did
not reach statistical significance. Patients continued to be
followed up for survival and in the final analysis of overall
survival at the time of data cutoff (February 27, 2009),
whereas 126 deaths had occurred (67 in the gefitinib treat-
ment group and 59 in the docetaxel treatment group); the
hazard ratio was 0.870 (95% CI, 0.613-1.236; two-sided P
= 0.4370; Fig. 3).
Quality of life and symptom improvement. Similar pro-
portions of patients in each treatment group experienced
an improvement in quality of life as measured by FACT-L
total score and in lung cancer symptoms as measured by
FACT-L Lung Cancer Subscale (FACT-L, 27.9% versus
27.3%, P = 0.9310; Lung Cancer Subscale, 39.7% versus
37.9%, P = 0.8282; Fig. 4). A numerical but not statistical-
ly greater proportion of patients experienced an improve-www.aacrjournals.org
Researc
on Decembclincancerres.aacrjournals.org Downloaded from ment in quality of life with gefitinib than with docetaxel as
measured by the Trial Outcome Index (26.5% versus
13.6%; P = 0.0641; Fig. 4).
Safety and tolerability. Adverse events were generally
mild (National Cancer Institute Common Terminology
Criteria for Adverse Events grade 1 or 2) and consistent
with the underlying disease and toxicity profiles previ-
ously seen with each treatment (Table 2). Serious ad-
verse events were reported by 16% of gefitinib-treated
patients and 25% of docetaxel-treated patients. There
were four adverse events leading to death in the gefiti-
nib arm (pneumonia, septic shock, interstitial lung dis-
ease; two cases, one considered possibly treatment
related) and two in the docetaxel arm (pneumonia
and aspiration pneumonia). The incidence of interstitial
lung disease–type adverse events was 3.7% (three pa-
tients) with gefitinib and 3.9% (three patients) with
docetaxel. No interstitial lung disease–type adverse
events resulted in death in the docetaxel arm. Fewer
dose modifications due to toxicity occurred with gefiti-
nib (4.9% dose interruptions) than with docetaxel
(17.1% dose reductions or delays).
Postdiscontinuation treatment. At the time of the final
overall survival analysis (February 27, 2009), 1% patients
still received randomized study treatment in the gefitinib
group, whereas 24.7% received no further systemic che-
motherapy apart from further EGFR tyrosine kinase inhib-
itor (2.5% gefitinib/erlotinib; 22.2% no treatment), 29.6%
received docetaxel and 44.4% received other chemothera-
py. In the docetaxel group, 26.3% patients received no fur-
ther systemic therapy apart from docetaxel (1.3%
docetaxel; 25.0% no treatment), 67.1% received an EGFR
tyrosine kinase inhibitor, and 6.6% received other chemo-
therapy.
Discussion
ISTANA is the first phase III study showing an advantage
of molecularly targeted therapy to cytotoxic chemotherapyFig. 4. Improvement rates for quality of life (evaluable for quality of
life population). P values derived from χ2 test. Clinically relevant
improvement was defined as 6-point improvement for FACT-L and Trial
Outcome Index and 2-point improvement for Lung Cancer Subscale
maintained for ≥21 d. TOI, Trial Outcomes Index; LCS, Lung Cancer
Subscale.Clin Cancer Res; 16(4) February 15, 2010 1311
h. 
er 23, 2013. © 2010 American Association for Cancer
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Published OnlineFirst February 15, 2010; DOI: 10.1158/1078-0432.CCR-09-1903 as second-line therapy for NSCLC; gefitinib treatment
showed longer progression-free survival compared with
docetaxel (hazard ratio, 0.729; 90% CI, 0.533-0.998) with
significantly improved objective response rate (28.1% ver-
sus 7.6%) in Korean patients.
Two recently reported phase III studies, IRESSA in
NSCLC Trial Evaluating REsponse and Survival versus
Taxotere (INTEREST) and V-15-32 (comparing gefitinib
with docetaxel in pretreated advanced NSCLC), have
shown equivalence or similar efficacy in terms of overall
survival (Table 3). INTEREST, a global study on 1,466
patients, showed noninferiority of gefitinib (250 mg/d)
relative to docetaxel (75 mg/m2 every 3 weeks) in terms
of overall survival, with similar progression-free survivalClin Cancer Res; 16(4) February 15, 2010
Researc
on Decembclincancerres.aacrjournals.org Downloaded from and objective response rate and a more favorable tolera-
bility and quality of life profile (7). The second study, V-
15-32, a Japanese study on 489 patients, failed to meet
its primary objective of showing noninferiority in overall
survival between gefitinib (250 mg/d) and docetaxel (60
mg/m2 every 3 weeks) but found no significant difference
between gefitinib and docetaxel in terms of overall
survival and progression-free survival and superior objec-
tive response rate for gefitinib (8).
The different results of the three studies might also be
derived from the different characteristics of the partici-
pating patients. ISTANA was a 100% second-line setting
study, and the proportion of never smokers and respon-
ders to gefitinib were slightly higher than the other twoTable 2. Most common adverse events (those occurring in at least 10% of patients in either treatment
group; evaluable-for-safety population)n (%) Gefitinib (n = 81)h. 
er 23, 2013. © 201Docetaxel (n = 76)All CTC grades CTC grade 3/4 All CTC gradesClinical C
0 American AssociatiCTC grade 3/4Gastrointestinal disorders
Diarrhea 21 (25.9) 1 (1.2) 12 (15.8) 0 (0.0)
Nausea 13 (16.0) 0 (0.0) 14 (18.4) 0 (0.0)
Constipation 9 (11.1) 0 (0.0) 9 (11.8) 0 (0.0)
Vomiting 4 (4.9) 0 (0.0) 8 (10.5) 0 (0.0)
Stomatitis* 3 (3.7) 0 (0.0) 9 (11.8) 1 (1.3)
Dyspepsia 10 (12.3) 0 (0.0) 5 (6.6) 0 (0.0)General disorders
Asthenic conditions* 20 (24.7) 1 (1.2) 28 (36.8) 3 (3.9)
Chest pain 7 (8.6) 0 (0.0) 12 (15.8) 0 (0.0)
Pain 8 (9.9) 2 (2.5) 5 (6.6) 0 (0.0)Metabolism and nutrition disorders
Anorexia* 29 (35.8) 0 (0.0) 36 (47.4) 2 (2.6)Musculoskeletal and connective tissue disorders
Myalgia 4 (4.9) 0 (0.0) 29 (38.2) 0 (0.0)
Arthralgia 3 (3.7) 0 (0.0) 9 (11.8) 0 (0.0)Nervous system disorders
Neurotoxicity* 17 (21.0) 0 (0.0) 21 (27.6) 0 (0.0)
Dizziness 9 (11.1) 0 (0.0) 7 (9.2) 0 (0.0)Psychiatric disorders
Insomnia 13 (16.0) 0 (0.0) 18 (23.7) 0 (0.0)Respiratory, thoracic, and mediastinal disorders
Cough 25 (30.9) 0 (0.0) 25 (32.9) 0 (0.0)
Dyspnea 20 (24.7) 3 (3.7) 21 (27.6) 3 (3.9)
Productive cough 21 (25.9) 0 (0.0) 18 (23.7) 0 (0.0)
Hemoptysis 9 (11.1) 0 (0.0) 4 (5.3) 0 (0.0)Skin and s.c. disorders
Rash acneiform* 61 (75.3) 3 (3.7) 6 (7.9) 0 (0.0)
Pruritus* 40 (49.4) 2 (2.5) 5 (6.6) 1 (1.3)
Alopecia 4 (4.9) 0 (0.0) 33 (43.4) 0 (0.0)
Dry skin 12 (14.8) 0 (0.0) 0 (0.0) 0 (0.0)
Nail and nail bed conditions* 2 (2.5) 0 (0.0) 9 (11.8) (0.0)Abbreviation: CTC, common toxicity criteria.
*Grouped term (sum of several preferred terms).ancer Research
on for Cancer
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Published OnlineFirst February 15, 2010; DOI: 10.1158/1078-0432.CCR-09-1903 studies. In addition, all patients in ISTANA were Korean
or East Asian unlike INTEREST (Table 3). The prevalence
of EGFR gene mutations in Korean lung cancer patients
was reportedly 17.4% to 18.9%; however, it might be
slightly higher than in Western countries (9–12). Be-
cause gefitinib is associated with better efficacy in never
smokers who are more likely to harbor EGFR mutations,
these differences may have driven the overall result to-
ward superiority of gefitinib to docetaxel in terms of
progression-free survival. Furthermore, the final analysis
showed that gefitinib treatment showed a numerical im-
provement in overall survival (median survival, 14.1 ver-
sus 12.2 months) compared with docetaxel treatment,
although this failed to reach statistical significance,
which might be due to cross-over effect on overall sur-
vival. Early nontoxic treatment might be beneficial if
there are effective treatments, which is a potential hy-
pothesis to be assessed in a further study. In addition,
IPASS study also showed that gefitinib is superior to cy-
totoxic chemotherapy as first-line therapy, although the
patients enrolled were nonsmoker or former light
smoker with adenocarcinoma histology, as well as East
Asians (13).
Some may highlight the following potential limita-
tions of our study: 1) its primary endpoint was progres-
sion-free survival; 2) its sample size was smaller than
other similar studies; and 3) its study population was
selected (only Korean or Asian ethnicity patients and awww.aacrjournals.org
Researc
on Decembclincancerres.aacrjournals.org Downloaded from higher proportion of never smokers and patients with
adenocarcinoma histology). However, progression-free
survival is a clinically meaningful endpoint that repre-
sents a direct benefit to the patient and is largely unaf-
fected by postdiscontinuation therapies, which have
complicated the interpretation of survival data in other
similar studies in this setting. The sample size was rela-
tively small; however, an advantage for gefitinib over
docetaxel in the primary progression-free survival end-
point was still shown. Compared with INTEREST, the
proportion of never smokers and patients with adeno-
carcinoma histology was higher, and all patients were
Korean, which might have translated into the higher re-
sponse. However, considering that the patients were
broadly representative of a pretreated advanced NSCLC
study population in Korea (14, 15) and patient char-
acteristics were well balanced in the two treatment
groups (with the exception of never-smoking status,
which tended to be slightly lower in the gefitinib-
treated group; 37% versus 46%), the study is likely to
represent the true effect of gefitinib versus docetaxel in
Korean patients.
Before ISTANA was commenced, we decided not to as-
sess biomarkers because the sample numbers might be too
small to reach any robust conclusions, given that we ex-
pected tissue samples might be available only in <30%
to 40% of patients enrolled. In addition, EGFR gene mu-
tation or amplification has not yet been confirmed to be aTable 3. Phase III studies comparing gefitinib with docetaxelStudy INTEREST7 (N = 1,499)h. 
er 23, 201V-15-328 (N = 489)Clin Cance
3. © 2010 AmericanISTANA (current; N = 161)Patient characteristics, n (%)
Asian ethnicity 323 (22.0) 489 (100) 161 (100)
Female 512 (34.9) 187 (38.2) 61 (37.9)
Never smoker 298 (20.3) 158 (32.3) 66 (41.0)
WHO PS 0 or 1 1,290 (88.0) 468 (95.7) 150 (93.2)
Adenocarcinoma 830 (56.6) 380 (77.7) 110 (68.3)
Responders (CR/PR) to previous chemotherapy 428 (29.2) 219 (44.8) 58 (36.0)
Second-line therapy 1,229 (83.8) 413 (84.5) 161 (100)Treatment outcomes (gefitinib vs docetaxel)
OS; HR, 95% CI (median); mo 1.02, 0.91-1.15*
(7.6 vs 8.0)
1.12, 0.89-1.40
(11.5 vs 14.0)0.87, 0.61-1.24
(14.1 vs 12.2)PFS; HR, 95% CI (median); mo 1.04, 0.93-1.18
(2.2 vs 2.7)0.90, 0.72-1.12
(2.0 vs 2.0)0.73, 0.53-1.0†
(3.3 vs 3.4)
ORR, % (P) 9.1 vs 7.6 (0.3257) 22.5 vs 12.8 (0.009) 28.1 vs 7.6 (0.0007)
Quality of life improvement rates (gefitinib vs docetaxel)
FACT-L, % (P) 25.1 vs 14.7 (<0.0001) 23.4 vs 13.9 (0.023) 27.9 vs 27.3 (0.9310)
TOI, % (P) 17.3 vs 10.3 (0.0026) 20.5 vs 8.7 (0.002) 26.5 vs 13.6 (0.0641)
LCS, % (P) 20.4 vs 16.8 (0.1329) 22.7 vs 20.4 (0.562) 39.7 vs 37.9 (0.8282)Abbreviations: OS, overall survival; HR, hazard ratio; PFS, progression-free survival; ORR, objective response rate; TOI, Trial Out-
come Index; LCS, Lung Cancer Subscale.
*96% CI.
†90% CI.r Res; 16(4) February 15, 2010 1313
 Association for Cancer
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docetaxel.
Lastly, we did not find any statistically significant dif-
ference in quality of life improvement rates assessed by
FACT-L total score, Trial Outcome Index, and Lung Can-
cer Subscale, which might be partly because of the
small sample size. However, improvement of physical
or functional well-being domain was prominent in ge-
fitinib-treated patients (reflected in Trial Outcome In-
dex), but improvement of Lung Cancer Subscale
domain was similar, which is consistent with the other
two studies (7, 8). Unlike them, more patients with im-
provement of social/familial and emotional well-being
domains was observed in docetaxel-treated patients (da-
ta not presented), which should be studied further. Ad-
verse events in our study were consistent with those
previously reported. Gefitinib was associated with rash
acneiform, pruritus, rash, and diarrhea, whereas doce-
taxel was associated with alopecia and myalgia. Al-
though the hematologic toxicity was rather infrequent
in the docetaxel treatment group, this might be due
to infrequent examinations, meaning measurements
were not taken at the nadir.Clin Cancer Res; 16(4) February 15, 2010
Researc
on Decembclincancerres.aacrjournals.org Downloaded from In conclusion, gefitinib showed an advantage over doc-
etaxel in terms of progression-free survival and objective
response rate in Korean patients as second-line treatment,
and should be considered a preferred treatment option in
this clinical setting.
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